Approval · Notice of Compliance 1833 · 1999
ZOLADEX: Notice of Compliance 1833
Issued August 18, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1833
- Date
- August 18, 1999
- Company
- Zeneca Pharma Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for use as adjuvant hormone therapy to external beam irradiation for patients with locally advanced prostate cancer (stage T3-T4)
- Therapeutic class
- Luteinizing hormone - releasing hormone analog
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOLADEX | Not yet assigned | — |
Medicinal ingredients
- GOSERELIN ACETATE 3.6 MG per SYR
- GOSERELIN ACETATE 10.8 MG per SYR